Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals (MXC) has appointed Nicole Godresse as Global Chief Sales Officer, effective immediately
- Nicole has more than 20 years experience in the pharmaceutical and healthcare industries, having worked with the likes of Johnson & Johnson and Eli Lilly
- Her most recent role at Tilray saw her play a part in launching the first medical cannabis brand legally in Australia and New Zealand
- She also helped launch one of the first medical cannabis clinics in the country and deliver some of Australia’s first government-funded medical cannabis trials
- At MGC Pharma, Nicole will lead the company’s global sales and marketing and build a strong sales strategy by recruiting an experienced team
- MGC Pharma is up 3.85 per cent on the back of this news with shares trading at 2.7 cents
MGC Pharmaceuticals (MXC) has appointed Nicole Godresse as Global Chief Sales Officer, effective immediately.
Nicole has more than 20 years experience in the pharmaceutical and healthcare industries, having worked with the likes of Johnson & Johnson, Eli Lilly, and Merck Sharp.
In her most recent role of General Manager ANZ and Director of Emerging Markets at Tilray, Nicole played a major role in launching the first medical cannabis brand legally in Australia and New Zealand.
This role also saw her launch one of the first medical cannabis clinics in Australia and deliver some of Australia’s first government-funded medical cannabis trials.
These roles enabled Nicole to develop market knowledge and experience as well as build a strong network of government, customer and industry stakeholders.
At MGC Pharma, Nicole will lead the company’s global sales and marketing across Australia and New Zealand and build a strong sales strategy by recruiting an experienced team.
“We are delighted to welcome Nicole to the team and are extremely impressed with her experience and expertise,” Co-Founder and Managing Director Roby Zomer said.
“MGC Pharma delivered significant commercial progress during 2020 and we are focused on ensuring this trajectory continues with a new and refocused accelerated growth strategy,” he added.
MGC Pharma is up 3.85 per cent on the back of this news with shares trading at 2.7 cents at 1:57 pm AEDT.
